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A Ab bs st tr ra ac ct t
Advances in mass spectrometry have had a great impact on the field of proteomics. A major
challenge of proteomic analysis has been the elucidation of glycan modifications of proteins in
complex proteomes. Glycosylation is the most structurally elaborate and diverse type of protein
post-translational modification and, because of this, proteomics and glycomics have largely
developed independently. However, given that such a large proportion of proteins contain glycan
modifications, and that these may be important for their function or may produce biologically
relevant protein variation, a convergence of the fields of glycomics and proteomics would be
highly desirable. Here we review the current status of glycoproteomic efforts, focusing on the
identification of glycoproteins as cancer biomarkers.
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I In nt tr ro od du uc ct ti io on n
The sequencing of the human genome and the spectacular
advances in mass spectrometry (MS) have had a substantial
impact on the field of proteomics. MS has evolved from a
tool for the identification and characterization of isolated
proteins (mass peak profiling) to a platform for interro-
gating complex proteomes and identifying differentially
expressed proteins, whether in cells, tissues, or body fluids,
by matching mass spectra to sequence databases.
Remaining challenges that are gradually being conquered
include increased depth and throughput of proteomic
analysis and increased emphasis on elucidation of post-
translational modifications. Elucidation of glycan
modifications of proteins in complex proteomes has been a
major challenge for proteomics. Glycosylation is the most
structurally elaborate and diverse kind of protein post-
translational modification and has been shown to have
significant impact on protein function and confirmation. It
has been shown that more than half of all proteins in
human serum are glycosylated [1], so glycoproteins are
particularly interesting in serum diagnostics for cancer and
other diseases. Glycomics and proteomics have largely
developed independently, but a convergence of the two
fields is highly desirable.
Here we review the current status of glycoproteomic efforts
relevant to the identification of cancer biomarkers. We also
discuss what lies ahead and various options for compre-
hensive analyses that encompass both the cancer proteome
and its related glycome in search of biomarkers for early
cancer detection, for disease classification, and for
monitoring response to cancer therapy.G Gl ly yc co op pr ro ot te ei in n   a al lt te er ra at ti io on ns s   i in n   c ca an nc ce er r
Glycan modification of proteins occurs primarily at
asparagine residues (N-linked glycans) and at serine or
threonine residues (O-linked glycans). Typically glyco-
proteins that have complex glycan structures are membrane-
bound or secreted. Proteins with glycosylation that are pre-
dominantly nuclear or cytoplasmic often have a mono-
saccharide  O-linked  N-acetylglucosamine (O-GlcNAc) at
serine residues, which is also a site of protein phosphory-
lation. Research going back several decades has yielded
evidence that glycosylation is altered in cancer. Some cancer
cells have proteins with such differences in glycosylation
from non-cancerous cells that the proteins are categorized as
tumor-associated antigens, and they may even elicit a
humoral immune response, as reviewed a quarter of a
century ago by Hakomori [2] and recently by others [3].
Many initial studies with naturally occurring and hybridoma-
derived monoclonal antibodies that were targeted against
tumor antigens yielded evidence of reactivity that was
directed against carbohydrate epitopes, as in the case of so-
called oncofetal antigens [4]. Some glycomic alterations
found in cancer cells have been attributed to the activity and
localization in the Golgi of glycosyltranferases.
Mucins are among the most investigated glycoproteins pro-
duced by epithelial cancer cells. Mucins contain numerous
O-glycans that are clustered along the Ser/Thr/Pro-rich
‘variable number of tandem repeat’ (VNTR) domains and
have several cancer-associated structures, including the
Thomsen-Fredenreich antigen (T-antigen), the Thomsen-
nouveau antigen (Tn-antigen), and certain Lewis antigens
[5]. Cell-surface-bound and secreted mucin glycoproteins
contain  N-acetylgalactosamine (GalNAc)-Ser/Thr O-linked
sugars that constitute more than half of the mass of the
mucin. The glycans of mucins expressed on the cell surface
are involved in interactions with the microenvironment.
Several well known cancer serological biomarkers are mucins
or mucin-like glycoproteins, including tumor-associated
antigens cancer antigen 125 (CA125), cancer antigen 19-9
(CA19-9), cancer antigen 15-3 (CA15-3), and cancer antigen
72-4 (CA72-4). The discovery of CA125 resulted from an
assay developed using a murine monoclonal antibody that
reacts with an antigen found to be common to most non-
mucinous epithelial ovarian carcinomas [6]. The application
of this assay showed that only 1% of 888 apparently healthy
subjects and 6% of 143 patients with non-malignant disease
had serum CA125 levels above 35 units (U)/ml. In contrast,
83 of 101 patients with surgically demonstrated ovarian
carcinoma had elevated levels of antigen above 35 U/ml [6].
CA125 was subsequently identified as a new mucin, mucin 16
(MUC16) [7]. CA19-9 is a tumor marker for pancreatic
cancer that resulted from the development of a monoclonal
antibody [8] that was found to interact with sialyl-Lewis a
(sLea) antigen on pancreatic carcinoma mucins [9,10]. CA15-3
is the antigen expressed on mucin 1 (MUC1) in breast cancer
that was defined by two monoclonal antibodies raised
against breast cancer cells [11]. CA72-4 is a marker for
epithelial-cell-derived tumors resulting from the develop-
ment of murine monoclonal antibodies that recognized
TAG-72, a mucin-like protein, in human serum [12]. Although
these glycoproteins do not show optimal performance as
screening tests for cancer, they have utility for monitoring
disease progression because their serum levels correlate with
tumor mass.
Some mucins can be identified and quantified in serum and
plasma by proteomic analysis. For example, in the Human
Proteome Organisation plasma proteome study [13],
MUC16/CA125, a large protein with 22,152 amino acids and
mass of 2.35 MDa before glycosylation, was well represented
among the identified proteins. Its plasma concentration by
immunoassay was only 67 pg/ml, yet as many as 15 MUC16
peptides were observed in some analyses using glycoprotein
enrichment. Even without glycoprotein enrichment but with
some fractionation before MS analysis of individual frac-
tions, we have identified a large number of mucins in plasma
studies (Table 1). A snapshot of the peptide representation
for MUC16 in these data is shown in Figure 1. Despite the
substantial peptide identifications derived from MUC16, the
lack of identified peptides (red rectangles) overlapping
glycosylation sites (black bars) demonstrates that domains
containing glycan modifications fail to be identified in a
traditional shotgun proteomic analysis.
Some effort in proteomics has focused on glycoproteins
because of their biological significance and importance as a
source of biomarkers. Much of the effort has used enrich-
ment of glycoproteins followed by identification through
MS analysis of non-glycosylated or deglycosylated peptides,
without elucidating any disease-associated glycan modifica-
tions. Glycomic approaches have mainly been focused on
the analysis of individual targeted glycoproteins obtained
through a preparative process, followed by detailed analysis
of their glycan composition and structure, without making
full use of the capabilities of proteomics. A more glycan-
informative approach is outlined by the flow chart in
Figure 2, which reflects the integration of traditional
proteomics methods with glycomics techniques. In this
methodology, glycoproteins can be enriched by using their
affinity for lectins, which bind to specific glycans, followed
by MS analysis. Glycoproteins can then be classified on the
basis of their lectin-binding properties. Furthermore, im-
proved glycoproteomic technologies and methodologies
enable detailed glycan structure analysis and sequencing of
glycopeptide backbones. Glycopeptides can be enriched
and/or fractionated by lectin affinity followed by MS
analysis of glycan structures in parallel with peptide
sequencing of deglycosylated peptides by MS analysis.
Alternative approaches to MS for glycoprotein profiling
include lectin affinity array-based analyses with which
glycoproteins in complex mixtures are sub-classified
according to their binding to lectin arrays, and are then
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G Gl ly yc ca an n   p pr ro of fi il li in ng g   i in n   c ca an nc ce er r
Efforts to elucidate the spectrum of glycan alterations
associated with particular tumor types have accelerated
because of methodological improvements, as exemplified by
two breast cancer studies that include the analysis of glycans
from tumor tissue and cells [14] and the analysis of serum
and other biological fluids [15]. An approach using tumor
tissue or cells takes advantage of knowledge that has been
derived from studies at multiple levels. Abbott et al. [16]
used a glycosyl-transferase-directed approach that used the
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IPI Gene Description Length (aa) MW N
IPI00552461 CD164L2 Cd164 sialomucin-like 2 171 17,874 2
IPI00452565 EMCN Isoform 1 of endomucin precursor 261 27,452 2
IPI00452566 EMCN Isoform 2 of endomucin precursor 178 18,848 1
IPI00400813 EMR4 Isoform 2 of putative EGF-like module-containing mucin-like hormone  474 52,857 1
receptor-like 4 precursor
IPI00289931 MADCAM1 Isoform 1 of mucosal addressin cell adhesion molecule 1 precursor 406 42,691 24
IPI00397424 MADCAM1 Mucosal vascular addressin cell adhesion molecule 1 isoform a precursor 382 40,155 1
IPI00016334 MCAM Isoform 1 of cell surface glycoprotein muc18 precursor 646 71,607 69
IPI00445227 MCAM Isoform 2 of cell surface glycoprotein muc18 precursor 527 57,605 43
IPI00013955 MUC1 Isoform 1 of mucin-1 precursor 1,255 122,072 9
IPI00103552 MUC16 Mucin-16 22,152 2353428 18
IPI00646572 MUC16 Uncharacterized protein muc16 14,495 1518170 61
IPI00384775 MUC17 Small intestinal mucin muc3 (fragment) 648 65,520 1
IPI00470673 MUC17 Isoform 1 of mucin-17 precursor 4,493 451,723 1
IPI00737886 MUC19 Similar to submaxillary apomucin 1,509 158,995 8
IPI00829796 MUC19 Muc19 246 23,202 1
IPI00027201 MUC2 Mucin-2 precursor 5,179 540,300 20
IPI00178316 MUC4 Isoform 12 of mucin-4 precursor 1,125 125,170 1
IPI00181286 MUC4 52 kDa protein 475 51,806 2
IPI00103397 MUC5AC Mucin-5ac precursor (fragment) 5,030 526,608 18
IPI00386327 MUC5AC Mucin-5ac (fragment) 1,233 130,073 2
IPI00479313 MUC5AC Gastric mucin (fragment) 1,373 147,788 1
IPI00744035 MUC5AC 591 kDa protein 5,709 591,191 3
IPI00869170 MUC5AC Mucin 5ac, oligomeric mucus/gel-forming 6,207 648,803 1
IPI00012165 MUC5B Predicted: mucin 5, subtype b, tracheobronchial 5,708 591,045 15
IPI00747373 MUC5B Mucin-5b precursor 5,703 590,499 1
IPI00401776 MUC6 Mucin 6, gastric 2,439 257,051 23
IPI00030366 MUC8 Mucin 274 29,038 51
IPI00180687 MUPCDH Isoform 3 of mucin and cadherin-like protein precursor 487 53,233 3
IPI00301869 MUPCDH Isoform 2 of mucin and cadherin-like protein precursor 651 69,541 1
IPI00029147 Mucin (fragment) 171 17,863 1
IPI00376207 Similar to muc19 598 61,206 1
IPI00398026 Predicted: similar to mucin-4 270 27,866 1
IPI00455879 Predicted: similar to mucin 1 precursor (muc-1)  879 93,058 8
IPI00457080 Predicted: similar to submaxillary apomucin 7,202 694,615 66
Abbreviations: aa, amino acids; IPI, International Protein Index [55]; MW, molecular weight; N, number of experiments. Descriptions are taken from
annotations in the IPI database.observation that N-acetylglucosaminyltransferase Va (GnT-Va)
transcript levels and activity are increased in breast cancer.
Elevated GnT-Va levels lead to increased β(1,6)-branched
N-linked glycan structures on glycoproteins that can be
measured using Phaseolus vulgaris leucoagglutinin lectin
(PHA-L). During the progression to invasive carcinoma, cells
show a progressive increase in PHA-L binding. A PHA-L-
affinity enrichment procedure, followed by nanospray
ionization tandem MS (NSI-MS/MS), was used to identify a
set of proteins enriched by the PHA-L-affinity fractionation
in tumor relative to normal tissue. These proteins could have
potential as breast cancer biomarkers [16].
Studies of serum and other biological fluids have followed a
variety of approaches. In a study by Adb Hamid et al. [17],
N-glycans of the total serum glycoproteins from breast
cancer patients and healthy controls were characterized by
high performance liquid chromatography (HPLC) with
fluorescence detection coupled with exoglycosidase diges-
tions and MS. A significant increase in a tri-sialylated tri-
antennary glycan-containing α1,3-linked fucose, which
forms part of the sialyl Lewis x (sLex) epitope, was observed
in cancer samples, and this led to the isolation of a mono-
galactosylated tri-antennary structure containing α1,3-
linked fucose. (Glycan structures with several branches are
referred to as bi-antennary, tri-antennary and so on.) This
glycan was found to occur at higher levels in serum from
breast cancer patients than in controls, with evidence of a
positive correlation between the glycan marker and disease
progression. The marker showed a stronger correlation with
metastasis than did CA15-3 or carcinoembryonic antigen.
The proteins α1-acid glycoprotein, α1-antichymotrypsin and
haptoglobin β-chain were identified as contributors to the
increase in the glycan marker.
Matrix assisted laser desorption ionization (MALDI)-MS has
been applied to glycomic profile analyses of biological fluids.
MALDI-MS analysis of permethylated glycans in sera from
breast cancer patients and disease-free controls identified
several sialylated and fucosylated N-glycan structures as
potential biomarkers [18]. Increases in sialylation and
fucosylation of glycan structures were associated with tumor
progression. The findings led to the suggestion that MS-
based  N-glycomic profiling of serum-derived constituents
holds promise for staging cancer progression.
In another study by Goldman et al. [19], enzymatically
released  N-glycans from serum glycoproteins of hepato-
cellular carcinoma (HCC), normal, and chronic liver disease
were profiled by MALDI-time of flight (TOF)-MS for quanti-
tative comparison of 83 N-glycans. The abundance of 57 N-
glycans was significantly altered in HCC patients compared
with controls. The combination of three selected glycans
could classify HCC with 90% sensitivity and 89% specificity
in an independent validation set.
Yet another glycan-centric approach applied to cancer used
immunoaffinity chromatography (IAC) to isolate and identify
potential cancer biomarker glycoproteins through their
disease-associated glycans [15]. Glycoproteins were selected
from plasma of disease-free and breast cancer patients with
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F Fi ig gu ur re e   1 1
Distribution of mucin 16 peptides identified by mass spectrometry along
part of the sequence of this large protein. Red rectangles, peptides
identified; black bars, potential sites of glycosylation; green sequence,
repeat domains that are heavily glycosylated. Note the lack of identified
peptides spanning glycosylation sites.
12000 12200 12400 12600
14800 15000 15200 15400
9200 9400 9600 9800
F Fi ig gu ur re e   2 2
Glycoproteomic flow chart reflecting the integration of traditional
proteomics methods with glycomic techniques. This addresses the need to
identify a glycoprotein (1), identify a glycosylation site (2), and determine
the structure of the glycan (3). The ability to successfully characterize
glycoproteins requires an emphasis on purification, enrichment, and
fractionation strategies at both the protein and peptide level.
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2an anti-Lewis x (Lex) IAC column. The selected proteins
were eluted with an acidic mobile phase and identified
following tryptic digestion, reversed-phase chromatographic
fractionation of the digest, and identification of peptides in
collected reversed-phase liquid chromatography (LC) frac-
tions by MALDI-MS/MS. Nine glycoproteins were found to
be potential breast cancer marker candidates because of
their increased levels in breast cancer patients.
G Gl ly yc co op pr ro ot te ei in n   c ca ap pt tu ur re e   f fr ro om m   b bi io ol lo og gi ic ca al l   f fl lu ui id ds s   f fo or r
p pr ro ot te eo om mi ic c   a an nd d   g gl ly yc ca an n   a an na al ly ys si is s
In the past decade, with the evolution of proteomics and the
availability of new analytical separation tools and advanced
MS instrumentation, we have observed a renaissance in the
use of lectins. Given the urgent need to discover cancer
biomarkers in readily available clinical samples, much of the
scientific interest and thus effort by investigators using
lectins has been their application to complex biological
samples, such as plasma and serum. Several laboratories
have reported on improved analytical methods using lectin
affinity chromatography (LAC) [20-24]. Given the complexity
and wide range of protein concentrations in the plasma/serum
proteome, most glycoproteomic workflows have incorporated
one of the several available methods for depletion of abundant
proteins as the first step in the fractionation of serum or
plasma. Lectins are being used singly, in serial combinations
or as mixtures of lectins [25-28].
Zhao  et al. [29] used three separate lectin-agarose conju-
gates consisting of wheat germ agglutinin (WGA), Sambucus
nigra lectin (SNA) and Maackia amurensis lectin (MAL) as
part of sample preparation to selectively enrich sialic-acid-
containing glycoproteins from human cancer serum. The
eluate from each lectin column was further separated using
other analytical separation methods (reversed-phase HPLC,
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and glycopeptide mapping). Proteins that
showed profile differences were first identified by peptide
sequencing using LC-MS/MS. Glycopeptide mapping from
the target proteins was performed in parallel using LC-
electrospray ionization (ESI)-TOF-MS to determine changes
in the carbohydrate structure and to identify altered
glycosylation sites in the cancer serum samples. In this work
[29], a change in glycosylation site occupancy, such as at
Asn83, was observed for α-1 anti-trypsin in pancreatic
cancer compared with the control sample. Thus, the strategy
of combining targeted glycoprotein enrichment with MS
analysis enabled an assessment of changes both in the
abundance of the glycoprotein and in the glycosylation state
of the protein.
S Se er ri ia al l   l le ec ct ti in n   a af ff fi in ni it ty y   c ch hr ro om ma at to og gr ra ap ph hy y
Other lectin chromatography approaches, such as serial
lectin affinity chromatography (SLAC), have relied on
multiple lectins so that different subsets of glycoproteins can
be targeted simultaneously to compare and detect changes in
glycosylation patterns or to elucidate structural differences
between glycoforms. SLAC involves a serial arrangement of
lectin columns, whereby the flow-through of the first column
is applied to the second column, and the flow-through from
the second column applied to a third, and so forth. The use
of SLAC for the enrichment of glycoproteins from complex
biological samples requires a careful evaluation and optimi-
zation of the order of lectins, as well as the tailoring of lectin
types to be used in series, in order to minimize overlap in
binding specificity.
The application of SLAC is best demonstrated by the work of
Sumi et al. [30], who proposed that N-acetylglucosaminyl-
transferase IV is upregulated in patients with early stage
prostate cancer compared with those with benign prostatic
hyperplasia. This was determined by monitoring the elution
of prostate-specific antigen from a SLAC system consisting
of Concanavalin A (ConA), WGA, Pisum sativum PS,
Phaseolus vulgaris erythroagglutinin, and Phaseolus vulgaris
erythroagglutinin L4 lectin columns. Less binding of prostate-
specific antigen to ConA and PS was observed in prostate
cancer than in benign prostatic hyperplasia, indicating a shift
from bi-antennary complex glycoforms to multi-antennary
structures with branched GlcNAc oligosaccharides.
In another application, Qiu and Regnier [31] used a SNA
column inline with a ConA column to enrich glycopeptides
instead of glycoproteins containing sialylated complex
N-linked glycans from human serum. Serum samples were
digested with trypsin and fractionated over the SLAC
system. Glycopeptide fractions were then isotopically labeled
with heavy and light tags and deglycosylated with peptide-N-
glycosidase F before analysis by LC-MS. A quantitative com-
parison of the bound and unbound fractions eluting from the
ConA column showed that bi-antennary N-linked glycoforms
were present in higher concentrations than tri- and tetra-
antennary N-linked glycoforms in serum. Different degrees of
N-linked glycan branching were also detected in the case of
ferroxidase. Two glycopeptides were detected for ferroxidase
but were observed in different ratios, indicating a different
degree of binding of these glycoforms to ConA and variable
glycan branching at different sites in the same protein.
M Mu ul lt ti i- -l le ec ct ti in n   a af ff fi in ni it ty y   c ch hr ro om ma at to og gr ra ap ph hy y
A strategy introduced by Yang and Hancock [32], designated
multi-lectin affinity chromatography (M-LAC), uses physical
admixtures of different immobilized lectins. This approach is
based on the well established ‘glycoside cluster effect’, in
which binding affinities can be dramatically increased by a
clustering of both lectin binding sites and carbohydrate
recognition units on the surface of cells or tissues [33]. Using
kinetic measurements of a printed panel of lectins using
elliptically polarized light (LFIRE) [25], the binding strength
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using a multi-lectin strategy, suggesting that this approach
can indeed lead to greater functional avidity than the use of
individual lectins. For example, the binding affinity of
thyroglobulin for the mixture of lectins (Ka = 2.1 × 106 M-1)
was found to be about 6 and 15 times higher than the
corresponding individual lectins, ConA (3.4 × 105 M-1) and
WGA (1.4 × 105 M-1), respectively [25].
In addition to affinity enhancement effects, the incorpora-
tion of different ligands into a multi-ligand cluster can give
rise to exquisite selectivity for specific glycan structures. For
example, the M-LAC column that combines ConA, WGA,
and Jacalin (a lectin derived from seeds of the jackfruit
Artocarpus integrifolia) has been optimized to capture the
majority of glycoproteins present in human serum or plasma
in a single step. Furthermore, because of the enhancement
in binding affinities it is possible to enrich for low- to
medium-level glycoproteins despite the large dynamic range
of concentrations in plasma and serum. In a M-LAC study of
serum samples collected from breast cancer patients, it was
possible to identify the cancer marker human epidermal
growth factor receptor 2 (HER-2) at a level of 5-20 ng/ml,
which was confirmed by enzyme-linked immunosorbent
assay (ELISA) quantification [34].
T Ta ar rg ge et te ed d   a an na al ly ys si is s   o of f   i in nd di iv vi id du ua al l   g gl ly yc co op pr ro ot te ei in ns s
The targeted analysis of specific glycoproteins is performed
to elucidate details of the glycan structures associated with
those glycoproteins. Studies have been performed by
purifying proteins followed by glycomic analysis of cleaved
glycan structures or analysis of glycans attached to intact
glycopeptides, enabling identification of glycan structure
and peptide sequence. White et al. [35] used a glycomic
approach to characterize glycans cleaved from prostate-
specific antigen and prostatic acid phosphatase purified
from seminal samples representative of normal controls,
benign prostatic disease, and prostate cancer patients. The
cleaved glycans were permethlyated by chemically convert-
ing them to methylated derivatives, which improves MS
analysis and stabilizes sialic acids and has, therefore,
become a common method in glycomics analysis. The
released  N-linked glycan constituents of both proteins by
normal phase HPLC and MALDI-TOF MS resulted in 40
putative glycoforms of prostate-specific antigen and 21
glycoforms of prostatic acid phosphatase.
A set of ongoing studies by Miyoshi and co-workers [36-39]
has characterized increased levels of fucosylated haptoglobin
in pancreatic cancer. They discovered elevated levels of
fucosylated haptoglobin in the serum of patients with
pancreatic cancer by western blot analyses using Aleruia
aurantica lectin. Subsequent LC-ESI-MS analyses of hapto-
globin purified from human serum of pancreatic cancer
patients and normal controls demonstrated that total
concentrations of fucosylated glycan of haptoglobin increased
in pancreatic cancer. Furthermore, tri-antennary N-glycans
containing Lex-type fucose increased at the Asn211 site of
haptoglobin in pancreatic cancer, and a di-fucosylated tetra-
antennary  N-glycan was observed only at this site in
pancreatic cancer patients.
In another study, the glycan structure analysis by LC-
MS/MS of intact glycopeptides of epidermal growth factor
receptor (EGFR) from the A431 epithelial carcinoma cell line
and four reference pools of plasma from healthy subjects
and patients with cancer resulted in identification of a
glycosylation site with a very different glycan structure in
human plasma than in the A431 cell-line-derived EGFR
(Figure 3) [40]. The four reference pools of plasma analyzed
resulted in the identification of peptides shown in Figure 3a.
Inspection of the identified peptides reveals that only
peptides from the extracellular domain of EGFR are found in
the plasma samples and only one peptide identification was
for a known glycosylation site. A detailed glycan structure
analysis of glycopeptides of EGFR from the A431 cell line
resulted in identification of ten proposed N-linked glycan
structures and glycosylation sites (Figure 3b) [41]. Glycan
analysis of the plasma samples known to contain EGFR
resulted in identification of a complex type glycan at
Asn328, which differed from the high-mannose glycan at
Asn328 in the A431 sample.
L Le ec ct ti in n   a af ff fi in ni it ty y   a as ss sa ay ys s
Lectin microarrays are also rapidly becoming a powerful tool
for glycosylation profiling studies [42]. An advantage of lectin
array platforms is that they allow highly parallel analysis of a
minimal amount of body fluid or biopsy material and have
good throughput and sensitivity. Recently, lectin-antibody
sandwich arrays have been used to screen for glycosylation
changes of target glycoproteins [43,44]. The use of an
antibody as capture agent confers specificity, and several
different fluorescently labeled lectins can be rapidly screened
to detect different patterns of glycan structures. Chen et al.
[43] found cancer-associated glycan alterations on the
proteins MUC1 and carcinoembryonic antigen in the serum
of pancreatic cancer patients compared with normal using a
lectin-antibody sandwich microarray. In another study by Li
et al. [44], antibodies for four potential glycoprotein markers
were printed onto microarrays and hybridized against serum
of 89 normal control, 35 chronic pancreatitis, 37 diabetic, and
22 pancreatic cancer samples. The captured glycoproteins
were then probed with four different fluorescently labeled
lectins in a sandwich array format, followed by characteri-
zation in situ by on-plate digestion and direct analysis using
MALDI-QIT (quadrupole ion trap)-TOF-MS. They show that
the response of α-1-β glycoprotein to SNA lectin was 69%
higher in the cancer sample than in the non-cancer groups,
resulting in the specific detection of pancreatic cancer with
high sensitivity and specificity.
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such as those using evanescent-field fluorescence assisted
detection [45] or LFIRE [25], are emerging and offer the
opportunity to detect carbohydrate-lectin interactions with
very high sensitivity. A new microarray procedure using an
evanescent-field fluorescence-detection principle has
allowed the sensitive measurement of multiple lectin-
carbohydrate interactions [46]. This method used 39
different lectins and allowed the quantitative detection of
even weak lectin-carbohydrate interactions (dissociation
constant, Kd > 10-6 M). Scanning ellipsometry was used to
profile glycosylation patterns from four different species
with a panel of eight different lectins immobilized on a gold
wafer [47].
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Identification of EGFR glycoforms. ( (a a) ) The extracellular-domain sequence of EGFR (629 amino acids) is shown at the top. Black bars, peptides that are
predicted to be generated by tryptic digestion; green boxes, peptides with known N-linked glycosylation sites; red boxes, peptides identified in a series of
four LC-MS/MS experiments to identify proteins in reference pools of plasma from healthy subjects and patients with cancer. A manual inspection for
known glycosylated peptides from EGFR was then carried out, leading to the identification of the peptide containing the Asn328 glycosylation (green box
in experiment 4). ( (b b) ) EGFR from the A431 cell line was subjected to MS analysis. Ten N-linked glycosylation sites were identified, and the main glycan
proposed to be at each site is shown [41]. Curly brackets indicate that the monomer (sialic acid) is present in one of these positions (or two in the case
of the glycan attached to Asn544). ( (c c) ) The proposed glycan structure for one EGFR peptide differs from that of the corresponding peptide identified in
A431 cells. This structure was determined following LC-MS/MS analysis of human plasma from a mixture of control individuals and patients with lung
cancer (SL Wu and BL Karger, personal communication). Reproduced with permission from [40].
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629 1Lectin affinity methods have potential as clinical assays for
glycan biomarker quantification. Recently, an assay of the
Lens culinaris agglutinin-reactive form of α-fetoprotein
(AFP-L3%) has been approved by the US Food and Drug
Administration as a diagnostic for HCC [48]. AFP is a
glycoprotein with a molecular weight of about 70 kDa and
has a single asparagine-linked carbohydrate chain. The level
of AFP in blood is currently used in the diagnosis of HCC.
However, AFP results are often not definitive until a tumor
has reached a large size or an advanced state. AFP has
positive predictive value ranges from 15% to 35%, with
limited detection of early stage disease and many false-
positive results. The study by Leerapun et al. [48]
demonstrated the utility of AFP-L3% as a prognostic marker
for HCC. They showed that for patients with indeterminate
total AFP values of 10-200 ng/ml, a ratio of AFP-L3% to
total AFP over 35% had 100% specificity for HCC.
Lectin affinity methods can be implemented as a targeted
glycoproteomic approach for accelerated glycan biomarker
discovery. The targeted glycoproteomic approach first uses
LAC to enrich for a selected set of protein glycoforms and
then uses lectin microarrays to screen for differences in
glycosylation patterns in a set of clinical samples. Further-
more, such a lectin approach can lead to the identification of
biomarker candidates solely on the basis of glycosylation
differences and not necessarily of changes in protein
abundance. The high-throughput capabilities of lectin arrays
could accommodate hundreds of clinical samples and
appropriate controls that can be rapidly screened with
several lectins to validate candidate markers that had been
discovered by MS-based glycomic studies.
T Th he e   n ne ee ed d   f fo or r   b be et tt te er r   g gl ly yc co op pr ro ot te eo om mi ic c   m me et th ho od ds s   a an nd d
p pl la at tf fo or rm ms s
To a large extent, proteomic approaches that rely on capture
of glycoproteins followed by removal of their glycans as a
means to allow identification of their protein constituents
have not yielded unique glycoprotein forms with cancer
specificity. Likewise, strategies to profile glycan constituents
in cancer have resulted in the identification of abundant
glycoproteins that show glycan changes related to processes
that are not cancer specific, such as inflammation and acute
phase response. Therefore, the approaches of stripping glycans
of their proteins or stripping proteins of their glycans,
followed by profiling of either glycans or protein ‘backbones’,
are low-yield strategies for defining glycoprotein forms
associated with cancer or other diseases. In addition, it is not
possible, despite substantial effort and some progress in
bioinformatics approaches, such as the program GlycoX
[36], to predict actual glycosylation sites in a given protein,
especially for O-glycosylation. There is a clear need for
improved strategies for mining the proteome and its
associated glycome to identify biomarkers and novel targets
for imaging and therapeutics.
There have been substantial recent developments in sample
preparation and MS methods to allow systematic analysis of
glycopeptides derived from biological samples, and quantifi-
cation of their glycan related isoforms, thus yielding identi-
fication of specific glycoforms associated with cancer as
potential biomarkers. Such characterization approaches,
when combined with lists of potentially glycosylated pep-
tides contained in databases such as UniPep [49], enable the
identification of a significant fraction of the glycoproteome
of a given sample. Examples of recent developments contri-
buting to glycoproteomics include improved analytical
methods by development of specific antibodies and lectin
capture agents, immobilized protease (pronase) reactors and
Fourier transform MS measurements [50], isotopically
labeled standard peptides [51], variable enzymatic deglyco-
sylation strategies combined with 18O incorporation [52],
and new MS approaches that use electron transfer disso-
ciation and collisionally associated dissociation fragmen-
tation of the target glycopeptides [53]. A good example of the
integration of such strategies is isotope-coded glycosylation-
site-specific tagging, in which a combination of lectin-based
capture methods, generation of peptide digests that are
fractionated by hydrophilic interaction chromatography,
peptide-N-glycanase-mediated incorporation of an 18O
stable isotope tag, and identification of 18O-tagged peptides
by LC-MS allowed identification of about 1,000 glyco-
proteins and their sites of glycosylation within a week from a
crude extract of the nematode Caenorhabditis elegans or of
mouse liver [54].
There are significant remaining challenges for the monitor-
ing of glycan changes of low-concentration glycoproteins
from clinical samples. The success of proteomics for
characterization of low-abundance proteins has driven the
development of the technologies and methodologies
enabling substantial progress towards defining the human
proteome; now there is a need to characterize glycoforms of
those proteins at even lower abundance. A major limitation
for detailed glycan analysis of clinical samples is the amount
of sample available, even with pooling strategies. The
progress of glycoproteomics will depend on the development
of improved technology and methods for glycoprotein and
glycopeptide enrichment, MS instrumentation capable of
defining both glycan structure and peptide backbone
sequence with high resolution and sensitivity, bioinformatics
software for detailed glycan structure analysis, and high-
throughput affinity assays for screening large sample sets. A
strategy for discovery and validation of glycan alterations in
cancer and other diseases will rely on MS for the discovery of
glycan alterations and on high-throughput affinity
approaches for validation of potential glycoforms as
biomarkers through analysis of large sample sets. The
eventual success of a validated clinical assay for glycan-
specific biomarkers will depend on development of
appropriate glycoprotein standards that will minimize
variability between individual samples and laboratories.
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